CLYM
Climb Bio, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Climb Bio has 5 disclosed suppliers and 0 disclosed customers in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceUnder the Asset Purchase Agreement, with respect to any "Product" (as such term is defined in the Asset Purchase Agreement), we are obligated to (i) make total payments of up to $157.5 million to Acelyrin upon the achievement of various development, regulatory and commercial milestones, (ii) pay royalties in the single-digit percentages, subject to specified reductions, to Acelyrin on worldwide net sales in a given calendar year, and (iii) make non-refundable and non-creditable payments to Acelyrin on sublicense income with rates ranging from the low single digit to mid teen percent depending on the stage of development of the most advanced Product at the time of such sublicense.
CLYM 10-Kaccession 0001193125-26-092546
SentenceFor example, under the license agreement with CRH, CRH is responsible for prosecuting and maintaining intellectual property protection for budoprutug in consultation with us.
CLYM 10-Kaccession 0001193125-26-092546
SentenceIn addition, we rely on Mabworks, a Chinese corporation, pursuant to the Mabworks Agreement, to conduct nonclinical studies of CLYM116 and to provide clinical supply of CLYM116 for these studies.
CLYM 10-Kaccession 0001193125-26-092546
SentenceThe ProBioGen Agreement granted us a non-exclusive license under certain know-how, patents and materials, to use cell lines in which ProBioGen's proprietary technology is applied, to research, develop, manufacture, use, sell, offer to sell, import or export budoprutug.
CLYM 10-Kaccession 0001193125-26-092546
SentenceWe currently rely on certain foreign or foreign-owned third-party vendors, including WuXi and its affiliates, to manufacture certain materials used in the development of our product candidates or to provide services in connection with such development activities.
CLYM 10-Kaccession 0001193125-26-092546
Climb Bio, Inc.
10.40
Largest filed tie
—
—
—
Expected move
Inputsstraddle ±19.7%
spot 10.25exp Nov 20ATM strike 10ATM straddle 2.38IV 123%